Shares of AngioDynamics, Inc. (NASDAQ:ANGO) have earned an average rating of “Hold” from the eight brokerages that are currently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, four have given a hold recommendation and two have assigned a buy recommendation to the company. The average twelve-month price target among brokerages that have issued a report on the stock in the last year is $18.00.
Several analysts have commented on the stock. Zacks Investment Research raised shares of AngioDynamics from a “hold” rating to a “buy” rating and set a $19.00 target price for the company in a research note on Tuesday, October 3rd. Canaccord Genuity reaffirmed a “hold” rating and issued a $17.00 target price on shares of AngioDynamics in a research note on Sunday, October 8th. TheStreet cut shares of AngioDynamics from a “b-” rating to a “c” rating in a research note on Tuesday, January 2nd. KeyCorp reaffirmed a “hold” rating on shares of AngioDynamics in a research note on Friday, September 29th. Finally, BidaskClub cut shares of AngioDynamics from a “hold” rating to a “sell” rating in a research note on Saturday, January 6th.
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in shares of AngioDynamics by 14.4% during the 2nd quarter. Vanguard Group Inc. now owns 1,938,115 shares of the medical instruments supplier’s stock valued at $31,416,000 after buying an additional 243,825 shares during the period. Broadfin Capital LLC grew its stake in shares of AngioDynamics by 14.9% during the 2nd quarter. Broadfin Capital LLC now owns 1,683,252 shares of the medical instruments supplier’s stock valued at $27,286,000 after buying an additional 217,800 shares during the period. Janus Henderson Group PLC grew its stake in shares of AngioDynamics by 49.4% during the 3rd quarter. Janus Henderson Group PLC now owns 1,439,873 shares of the medical instruments supplier’s stock valued at $24,607,000 after buying an additional 476,327 shares during the period. Northern Trust Corp grew its stake in shares of AngioDynamics by 14.9% during the 2nd quarter. Northern Trust Corp now owns 1,202,941 shares of the medical instruments supplier’s stock valued at $19,500,000 after buying an additional 155,951 shares during the period. Finally, Wells Fargo & Company MN grew its stake in shares of AngioDynamics by 0.9% during the 3rd quarter. Wells Fargo & Company MN now owns 1,025,233 shares of the medical instruments supplier’s stock valued at $17,521,000 after buying an additional 9,639 shares during the period. 95.23% of the stock is owned by institutional investors.
AngioDynamics (NASDAQ:ANGO) last released its earnings results on Thursday, January 4th. The medical instruments supplier reported $0.16 EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of $0.16. The firm had revenue of $86.70 million during the quarter, compared to analysts’ expectations of $88.15 million. AngioDynamics had a negative net margin of 2.27% and a positive return on equity of 4.63%. AngioDynamics’s revenue for the quarter was down 2.6% on a year-over-year basis. During the same period in the previous year, the company earned $0.19 EPS. equities analysts anticipate that AngioDynamics will post 0.68 earnings per share for the current year.
COPYRIGHT VIOLATION NOTICE: “Analysts Set AngioDynamics, Inc. (ANGO) Price Target at $18.00” was originally published by Markets Daily and is the sole property of of Markets Daily. If you are viewing this story on another publication, it was illegally copied and republished in violation of US & international trademark & copyright law. The original version of this story can be read at https://www.themarketsdaily.com/2018/01/13/analysts-set-angiodynamics-inc-ango-price-target-at-18-00.html.
AngioDynamics, Inc designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.